Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic.
Allergen immunotherapy
Allergy
Asthma
Biological agents
COVID-19
Coronavirus
Inhaled steroids
Prevention
Treatment
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
17
09
2020
revised:
17
01
2021
accepted:
22
01
2021
pubmed:
9
2
2021
medline:
9
2
2021
entrez:
8
2
2021
Statut:
ppublish
Résumé
The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic. We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context. Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as "I have no data" or "I don't know" to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations. The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic.
METHODS
METHODS
We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context.
RESULTS
RESULTS
Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as "I have no data" or "I don't know" to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations.
CONCLUSION
CONCLUSIONS
The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.
Identifiants
pubmed: 33552380
doi: 10.1016/j.waojou.2021.100515
pii: S1939-4551(21)00009-0
pmc: PMC7847410
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100515Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they do not have conflict of interests related to the contents of this article.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):106-10
pubmed: 27668056
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2020 Jul 14;:
pubmed: 32662819
Allergy. 2020 Jul;75(7):1543-1545
pubmed: 32358994
J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55
pubmed: 21122901
Clin Chest Med. 2019 Mar;40(1):179-192
pubmed: 30691711
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2592-2599.e3
pubmed: 32561497
Allergy. 2020 Nov;75(11):2775-2793
pubmed: 32511784
Manag Care. 2018 Sep;27(9):14
pubmed: 30216151
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Am J Rhinol Allergy. 2019 Mar;33(2):203-211
pubmed: 30587005
Curr Allergy Asthma Rep. 2018 Aug 15;18(10):50
pubmed: 30112587
Allergol Select. 2020 May 28;4:44-52
pubmed: 32568272
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
World Allergy Organ J. 2020 May 16;13(5):100124
pubmed: 32426089
World Allergy Organ J. 2020 May 16;13(5):100126
pubmed: 32426090
Lancet. 2019 Aug 3;394(10196):407-418
pubmed: 31230828
Drugs. 2018 Mar;78(4):505-511
pubmed: 29464664
FDA Consum. 2003 Sep-Oct;37(5):5
pubmed: 14666890
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5
pubmed: 32224232
Allergy Asthma Immunol Res. 2020 Sep;12(5):783-791
pubmed: 32638559
Ann Intern Med. 2017 Dec 19;167(12):876-881
pubmed: 29181536
Arch Virol. 2018 Apr;163(4):845-853
pubmed: 29327237
Allergy. 2020 Oct;75(10):2445-2476
pubmed: 32584441
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2144-2148
pubmed: 32418622
Allergy. 2020 Sep;75(9):2206-2218
pubmed: 32578235
Trop Med Int Health. 2020 Mar;25(3):278-280
pubmed: 32052514
Gut. 2010 Jan;59(1):21-30
pubmed: 19828470
Allergy. 2021 Mar;76(3):648-676
pubmed: 32531110
P T. 2016 Jun;41(6):355-6
pubmed: 27313431
J Allergy Clin Immunol. 2017 May;139(5):1411-1421
pubmed: 28477720
Ann Allergy Asthma Immunol. 2020 Dec;125(6):707-709
pubmed: 32745609
J Allergy Clin Immunol. 2020 Sep;146(3):541-542
pubmed: 32620309
J Investig Allergol Clin Immunol. 2020;30(6):459-461
pubmed: 32394897
J Invest Dermatol. 2015 Jan;135(1):13-15
pubmed: 25501377
Br J Dermatol. 2016 Dec;175(6):1405-1407
pubmed: 27639259
Ann Allergy Asthma Immunol. 2020 Oct;125(4):479-481
pubmed: 32693208
Curr Allergy Asthma Rep. 2018 Sep 26;18(11):60
pubmed: 30259201
Lancet. 2016 Oct 29;388(10056):2115-2127
pubmed: 27609408
World Allergy Organ J. 2020 May 14;13(5):100125
pubmed: 32411315
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Drug Discov. 2017 Apr 28;16(5):305
pubmed: 28450716
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Allergy. 2020 Mar 31;:
pubmed: 32233040
J Allergy Clin Immunol. 2020 Jul;146(1):203-206.e3
pubmed: 32333915